Ivermectin for Critically and Noncritically Ill Hospitalized Patients With COVID-19: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP).

Hashmi M, Haniffa R, Jayakumar D, Beane A, Lorenzi E, Berry LR, Nasir Khoso M, Ain Khan Q, Kumar A, Altaf Kidwai A, Hills TE, Annane D, Aryal D, Au C, Baillie K, Beasley R, Best-Lane J, Bonten M, Bradbury CA, Brunkhorst FM, Burrell A, Buxton M, Cecconi M, Cheng AC, Cove ME, de Jong M, Detry MA, Duffy E, Estcourt LJ, Fitzgerald M, Fowler R, Goossens H, Green C, Hays LMC, Higgins AM, Huang DT, Ichihara N, Koirala S, Lamontagne F, Lawler PR, Lewis RJ, Litton E, Mahon N, Marshall JC, McAuley DF, McGlothlin A, McGuinness S, McQuilten ZK, McVerry BJ, Mouncey PR, Morpeth S, Netea M, Orr K, Parke RL, Parker JC, Patanwala A, Peters S, Reyes LF, Rowan KM, Saito H, Saunders CT, Santos M, Seymour CW, Shankar-Hari M, Singh V, Slater M, Tambyah PA, Tong SYC, Turgeon AF, Turner AM, van de Veerdonk F, Weis S, Zarychanski R, McArthur CJ, Angus DC, Berry SM, Gordon AC, Derde LPG, Webb SA, Murthy S, Arabi Y, Nichol AD, and the Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) Investigators

Open source

DOI
10.1097/ccm.0000000000007134
Published
2026 Jul 1
Container
Critical care medicine
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1097/ccm.0000000000007134,
  title = {Ivermectin for Critically and Noncritically Ill Hospitalized Patients With COVID-19: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP).},
  author = {Hashmi M and Haniffa R and Jayakumar D and Beane A and Lorenzi E and Berry LR and Nasir Khoso M and Ain Khan Q and Kumar A and Altaf Kidwai A and Hills TE and Annane D and Aryal D and Au C and Baillie K and Beasley R and Best-Lane J and Bonten M and Bradbury CA and Brunkhorst FM and Burrell A and Buxton M and Cecconi M and Cheng AC and Cove ME and de Jong M and Detry MA and Duffy E and Estcourt LJ and Fitzgerald M and Fowler R and Goossens H and Green C and Hays LMC and Higgins AM and Huang DT and Ichihara N and Koirala S and Lamontagne F and Lawler PR and Lewis RJ and Litton E and Mahon N and Marshall JC and McAuley DF and McGlothlin A and McGuinness S and McQuilten ZK and McVerry BJ and Mouncey PR and Morpeth S and Netea M and Orr K and Parke RL and Parker JC and Patanwala A and Peters S and Reyes LF and Rowan KM and Saito H and Saunders CT and Santos M and Seymour CW and Shankar-Hari M and Singh V and Slater M and Tambyah PA and Tong SYC and Turgeon AF and Turner AM and van de Veerdonk F and Weis S and Zarychanski R and McArthur CJ and Angus DC and Berry SM and Gordon AC and Derde LPG and Webb SA and Murthy S and Arabi Y and Nichol AD and and the Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) Investigators},
  year = {2026},
  journal = {Critical care medicine},
  doi = {10.1097/ccm.0000000000007134},
  url = {https://doi.org/10.1097/ccm.0000000000007134}
}

RIS

TY  - JOUR
TI  - Ivermectin for Critically and Noncritically Ill Hospitalized Patients With COVID-19: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP).
AU  - Hashmi M
AU  - Haniffa R
AU  - Jayakumar D
AU  - Beane A
AU  - Lorenzi E
AU  - Berry LR
AU  - Nasir Khoso M
AU  - Ain Khan Q
AU  - Kumar A
AU  - Altaf Kidwai A
AU  - Hills TE
AU  - Annane D
AU  - Aryal D
AU  - Au C
AU  - Baillie K
AU  - Beasley R
AU  - Best-Lane J
AU  - Bonten M
AU  - Bradbury CA
AU  - Brunkhorst FM
AU  - Burrell A
AU  - Buxton M
AU  - Cecconi M
AU  - Cheng AC
AU  - Cove ME
AU  - de Jong M
AU  - Detry MA
AU  - Duffy E
AU  - Estcourt LJ
AU  - Fitzgerald M
AU  - Fowler R
AU  - Goossens H
AU  - Green C
AU  - Hays LMC
AU  - Higgins AM
AU  - Huang DT
AU  - Ichihara N
AU  - Koirala S
AU  - Lamontagne F
AU  - Lawler PR
AU  - Lewis RJ
AU  - Litton E
AU  - Mahon N
AU  - Marshall JC
AU  - McAuley DF
AU  - McGlothlin A
AU  - McGuinness S
AU  - McQuilten ZK
AU  - McVerry BJ
AU  - Mouncey PR
AU  - Morpeth S
AU  - Netea M
AU  - Orr K
AU  - Parke RL
AU  - Parker JC
AU  - Patanwala A
AU  - Peters S
AU  - Reyes LF
AU  - Rowan KM
AU  - Saito H
AU  - Saunders CT
AU  - Santos M
AU  - Seymour CW
AU  - Shankar-Hari M
AU  - Singh V
AU  - Slater M
AU  - Tambyah PA
AU  - Tong SYC
AU  - Turgeon AF
AU  - Turner AM
AU  - van de Veerdonk F
AU  - Weis S
AU  - Zarychanski R
AU  - McArthur CJ
AU  - Angus DC
AU  - Berry SM
AU  - Gordon AC
AU  - Derde LPG
AU  - Webb SA
AU  - Murthy S
AU  - Arabi Y
AU  - Nichol AD
AU  - and the Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) Investigators
PY  - 2026
JO  - Critical care medicine
DO  - 10.1097/ccm.0000000000007134
UR  - https://doi.org/10.1097/ccm.0000000000007134
ER  -

APA

M, H., R, H., D, J., A, B., E, L., LR, B., M, N. K., Q, A. K., A, K., A, A. K., TE, H., D, A., D, A., C, A., K, B., R, B., J, B., M, B., CA, B., FM, B., A, B., M, B., M, C., AC, C., ME, C., M, D. J., MA, D., E, D., LJ, E., M, F., R, F., H, G., C, G., LMC, H., AM, H., DT, H., N, I., S, K., F, L., PR, L., RJ, L., E, L., N, M., JC, M., DF, M., A, M., S, M., ZK, M., BJ, M., PR, M., S, M., M, N., K, O., RL, P., JC, P., A, P., S, P., LF, R., KM, R., H, S., CT, S., M, S., CW, S., M, S., V, S., M, S., PA, T., SYC, T., AF, T., AM, T., F, V. D. V., S, W., R, Z., CJ, M., DC, A., SM, B., AC, G., LPG, D., SA, W., S, M., Y, A., AD, N., & Investigators, A. T. R. E. M. A. P. T. F. C. P. (. (2026). Ivermectin for Critically and Noncritically Ill Hospitalized Patients With COVID-19: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP).. Critical care medicine. https://doi.org/10.1097/ccm.0000000000007134

Source records